Nuveen LLC Buys Shares of 415,378 Quanterix Corporation $QTRX

Key Points

• Nuveen LLC has acquired a new stake in Quanterix Corporation, purchasing 415,378 shares valued at approximately $2.7 million, representing 1.07% of the company's stock.
• Quanterix recently posted earnings showing a loss of ($0.47) per share, which was below analysts' expectations, and reported revenue of $24.48 million for the quarter.
• Institutional investors collectively own 86.48% of Quanterix Corporation's stock, with several firms increasing their stakes significantly in the first quarter.

Nuveen LLC acquired a new position in Quanterix Corporation (NASDAQ:QTRX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 415,378 shares of the company's stock, valued at approximately $2,704,000. Nuveen LLC owned approximately 1.07% of Quanterix at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in Quanterix by 61.0% in the first quarter. Invesco Ltd. now owns 54,194 shares of the company's stock worth $353,000 after purchasing an additional 20,540 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Quanterix by 9.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 292,805 shares of the company's stock worth $1,906,000 after acquiring an additional 26,190 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Quanterix by 49.2% in the first quarter. XTX Topco Ltd now owns 23,017 shares of the company's stock worth $150,000 after acquiring an additional 7,595 shares during the last quarter. Mount Lucas Management LP purchased a new stake in shares of Quanterix in the first quarter worth $285,000. Finally, Easterly Investment Partners LLC grew its stake in shares of Quanterix by 38.8% in the first quarter. Easterly Investment Partners LLC now owns 1,325,620 shares of the company's stock worth $8,630,000 after acquiring an additional 370,625 shares during the last quarter. Institutional investors own 86.48% of the company's stock.

Insider Buying and Selling at Quanterix

In other news, Director David R. Walt bought 123,990 shares of the stock in a transaction on Friday, June 13th. The shares were bought at an average price of $6.14 per share, with a total value of $761,298.60. Following the completion of the acquisition, the director owned 1,866,933 shares in the company, valued at $11,462,968.62. The trade was a 7.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William P. Donnelly bought 93,113 shares of the stock in a transaction on Friday, June 6th. The stock was purchased at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the acquisition, the director owned 139,094 shares of the company's stock, valued at $756,671.36. This trade represents a 202.50% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 463,113 shares of company stock worth $2,625,444 over the last ninety days. 6.80% of the stock is currently owned by insiders.

Quanterix Price Performance

Shares of Quanterix stock traded down $0.14 during trading on Wednesday, hitting $4.35. 464,161 shares of the company's stock traded hands, compared to its average volume of 783,968. Quanterix Corporation has a 1 year low of $4.05 and a 1 year high of $15.85. The stock has a market capitalization of $202.14 million, a P/E ratio of -2.39 and a beta of 1.03. The business has a 50-day simple moving average of $5.52 and a 200-day simple moving average of $5.91.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. The business had revenue of $24.48 million for the quarter, compared to analysts' expectations of $29.73 million. Quanterix has set its FY 2025 guidance at EPS. On average, equities analysts predict that Quanterix Corporation will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Wall Street Zen cut Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Canaccord Genuity Group reissued a "hold" rating and issued a $5.00 target price (down from $12.00) on shares of Quanterix in a research note on Monday, August 11th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $11.75.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.